Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR183 | P32249 | 6/20 | 0.41 |
| ▸ | PYGL | P06737 | 2/20 | 0.40 |
| ▸ | ITGB2 | P05107 | 3/20 | 0.40 |
| ▸ | ICAM1 | P05362 | 3/20 | 0.40 |
| ▸ | ITGAL | P20701 | 3/20 | 0.40 |
| ▸ | CCR2 | P41597 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2903091 | 1.00 | GPR183 (0.41) | GPR183PYGLITGB2ICAM1ITGAL | |
| SCHEMBL2903011 | 1.00 | GPR183 (0.41) | GPR183PYGLITGB2ICAM1ITGAL | |
| SCHEMBL2903013 | 1.00 | GPR183 (0.41) | GPR183PYGLITGB2ICAM1ITGAL | |
| SCHEMBL2898969 | 0.98 | PYGL (0.42) | GPR183PYGLITGB2ICAM1ITGAL | |
| SCHEMBL2898971 | 0.98 | PYGL (0.42) | GPR183PYGLITGB2ICAM1ITGAL | |
| SCHEMBL2898974 | 0.98 | PYGL (0.42) | GPR183PYGLITGB2ICAM1ITGAL | |
| SCHEMBL2898977 | 0.98 | PYGL (0.42) | GPR183PYGLITGB2ICAM1ITGAL | |
| SCHEMBL2904483 | 0.93 | GPR183 (0.46) | GPR183PYGLCCR2 | |
| SCHEMBL2904481 | 0.93 | GPR183 (0.46) | GPR183PYGLCCR2 | |
| SCHEMBL2902783 | 0.92 | GPR183 (0.39) | GPR183PYGLITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010506-B1 | DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | HOFFMANN LA ROCHE (CH) | 2010-08-04 | — | — | EP | claimed |
| US-7632829-B2 | Diazepan derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-12-15 | — | — | US | claimed |
| US-20070249589-A1 | Novel diazepan derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-10-25 | — | — | US | claimed |
| EP-2010506-B1 | DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | HOFFMANN LA ROCHE (CH) | 2010-08-04 | — | — | EP | disclosed |
| US-7632829-B2 | Diazepan derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-20070249589-A1 | Novel diazepan derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249589-A1 | Novel diazepan derivatives | CCR3, CCR1, CCR10 | GPR183 86/4885PYGL 4706/4885ITGB2 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.